Publication
Oral Recombinant Feline Interferon-Omega as an alternative immune modulation therapy in FIV positive cats : clinical and laboratory evaluation
| dc.contributor.author | Gil, S. | |
| dc.contributor.author | Leal, R.O. | |
| dc.contributor.author | McGahie, D. | |
| dc.contributor.author | Sepúlveda, N. | |
| dc.contributor.author | Duarte, A. | |
| dc.contributor.author | Niza, M.M.R.E. | |
| dc.contributor.author | Tavares, L. | |
| dc.date.accessioned | 2014-09-25T16:13:13Z | |
| dc.date.available | 2014-09-25T16:13:13Z | |
| dc.date.issued | 2014-02 | |
| dc.description | Articles in International Journals | por |
| dc.description.abstract | Recombinant-Feline Interferon-Omega (rFeIFN-ω) is an immune-modulator licensed for use subcutaneously in Feline Immunodeficiency virus (FIV) therapy. Despite oral protocols have been suggested, little is known about such use in FIV-infected cats. This study aimed to evaluate the clinical improvement, laboratory findings, concurrent viral excretion and acute phase proteins (APPs) in naturally FIV-infected cats under oral rFeIFN-ω therapy (0.1 MU/cat rFeIFN-ω PO, SID, 90 days). 11 FIV-positive cats were treated with oral rFeIFN-ω (PO Group). Results were compared to previous data from 7 FIV-positive cats treated with the subcutaneous licensed protocol (SC Group). Initial clinical scores were similar in both groups. Independently of the protocol, rFeIFN-ω induced a significant clinical improvement of treated cats. Concurrent viral excretion and APP’s variation were not significant in the PO Group. Oral rFeIFN-ω can be an effective alternative therapy for FIV-infected cats, being also an option for treatment follow-up in cats submitted to the licensed protocol. | por |
| dc.identifier.citation | Gil, S., et al. (2014). Oral Recombinant Feline Interferon-Omega as an alternative immune modulation therapy in FIV positive cats : clinical and laboratory evaluation. Research in Veterinary Science, 96(1), 79–85. doi: 10.1016/j.rvsc.2013.11.007 | por |
| dc.identifier.doi | 10.1016/j.rvsc.2013.11.007 | |
| dc.identifier.issn | 0034-5288 | |
| dc.identifier.uri | http://hdl.handle.net/10400.5/7211 | |
| dc.language.iso | eng | por |
| dc.peerreviewed | yes | por |
| dc.publisher | Elsevier Ltd. | por |
| dc.subject | Feline Immunodeficiency Virus (FIV) | por |
| dc.subject | Recombinant-Feline Interferon Omega (rFeIFN-ω) | por |
| dc.subject | Immune-modulation | por |
| dc.subject | Oral therapy | por |
| dc.title | Oral Recombinant Feline Interferon-Omega as an alternative immune modulation therapy in FIV positive cats : clinical and laboratory evaluation | por |
| dc.type | journal article | |
| dspace.entity.type | Publication | |
| oaire.citation.endPage | 85 | por |
| oaire.citation.startPage | 79 | por |
| oaire.citation.title | Research in Veterinary Science | por |
| oaire.citation.volume | 96(1) | por |
| rcaap.rights | openAccess | |
| rcaap.type | article | por |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- Oral Recombinant Feline Interferon-Omega as an alternative immune modulation therapy in FIV positive cats: Clinical and laboratory evaluation - TID.pdf
- Size:
- 254.42 KB
- Format:
- Adobe Portable Document Format
License bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- license.txt
- Size:
- 1.71 KB
- Format:
- Item-specific license agreed upon to submission
- Description: